Qure.ai's AI X-ray for Lung Nodules Gets USFDA Clearance

By By Rediff Money Desk, NEWDELHI
Jan 10, 2024 10:32
Qure.ai's AI-powered chest X-ray solution for lung nodule detection receives USFDA clearance, marking the company's 6th clearance for chest X-ray solutions.
New Delhi, Jan 10 (PTI) Medical imaging solutions provider Qure.ai on Wednesday said it has received clearance from US health regulator for its artificial intelligence-enabled X-ray for detection of lung nodules.

Qure's chest X-ray-based qXR-LN uses artificial intelligence (AI)to identify and localize lung nodules thereby helping in identifying potentially malignant pulmonary nodules, thus boosting the fight against lung cancer, the company said in a statement.

This also marks the 6th USFDA (United States Food and Drug Administration) clearance for Qure's chest X-ray based solutions, the company said.

The qXR for lung nodule is a cutting-edge detection software designed to identify and highlight regions indicative of suspected pulmonary nodules ranging from 6 to 30 mm in size.

Prashant Warier, Co-Founder and CEO of Qure.ai, said the company has already deployed and implemented this solution globally, and the USFDA clearance "marks yet another ground-breaking leap in our pioneering efforts to combat lung cancer".

"Our heightened emphasis on the North American marketplace solidifies our commitment to making a meaningful impact in the fight against this deadly disease and underscores our dedication to advancing healthcare through innovation, providing a transformative solution enhancing the early detection of cancer and ultimately improving patient outcomes," Warier said.
Read More On:
qure.aiaiartificial intelligencelung noduleschest x-rayusfdalung cancermedical imaginghealthcaretechnology
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2024 Rediff.com